1. A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations. (October 2022) Authors: Opdam, F.; Heymach, J.; Barve, M.; Wu, Y.L.; Gibson, N.; Sadrolhefazi, B.; Serra, J.; Yoh, K.; Yamamoto, N. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗